Navigation Links
Histogen Wins Appellate Court Hearing in SkinMedica Patent Case
Date:8/26/2013

San Diego, CA (PRWEB) August 26, 2013

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that the United States Court of Appeals for the Federal Circuit has affirmed a lower court decision that the Company does not infringe patents in the lawsuit that SkinMedica, Inc. filed against Histogen in 2009.

SkinMedica had previously sued the Company for infringement of United States Patent Nos. 6,372,494 (titled “Methods of making conditioned cell culture medium compositions”) and 7,118,746 (titled “Conditioned cell culture medium compositions and methods of use”). In 2011, the United States District Court for the Southern District of California granted the Company’s Motion for Summary Judgment, confirming a finding of noninfringement. SkinMedica appealed the Summary Judgment Order, and on August 23, 2013 was rebuffed again by the Federal Circuit.

“We are excited to have confirmation from the Federal Circuit Court of Appeals that Histogen’s technology is unique, and outside of SkinMedica’s patent rights,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “We look forward to continuing the rapid revenue growth we’re seeing in our skincare business through our current partners, bringing on new partners in the near future, and expanding the skin care line to other aesthetic applications.”

Histogen’s proprietary human multipotent cell conditioned media is the key ingredient in the ReGenica line of skincare products within the United States, and will be incorporated into additional cosmetic products in various countries through promising partnerships.

The Federal Circuit Court of Appeals affirmed the grant of Motion for Summary Judgment in case 2012-1560 following a hearing on May 9, 2013. A copy of the appellate court opinion is available upon request.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11059251.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
2. Genetic Testing Explodes after Supreme Court Patent Decision
3. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
4. Honey Bee Beekeeping Class at North Island College’s Courtenay Campus
5. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
6. Bed Bugs are On The Rise in Courts and Apartment Complexes; My Cleaning Products Offers Complimentary Samples of Its Bed Bug Spray To Bed Bug Victims
7. Non-Toxic Bed Bug Spray Offers Complimentary Sample to Court After a Man Infected It With Bed Bugs, My Cleaning Products Explains How Others Could Get a Sample
8. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
9. Case Zeltiq - CLINIPRO: The Court Upholds Clinipro - LipoCryo Claim
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... ... 10, 2016 , ... Benchmark Research, a fully-integrated network of ... long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research ... Laurence Chu, a Benchmark Research PI in the Austin office, will assume the ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... West conference in San Francisco’s Moscone Center from February 16-18, 2016, and at ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can with ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, ... 2014. More than 1,600 participants have joined the PROMPT study, which seeks to ...
Breaking Biology Technology:
(Date:1/27/2016)... Ohio , Jan. 27, 2016  Rite Track, ... based in West Chester, Ohio ... award winning service staff, based in Austin, ... capacity and ability to provide modifications, installations and technical ... Dovalina , CEO of PLUS, commented, "PLUS has provided ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
Breaking Biology News(10 mins):